ReviewCurrent opinion in supportive and palliative care2026
Practical prescribing in cancer cachexia.
Review in Current opinion in supportive and palliative care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewPatients with cancer cachexia have shorter survival, decreased response to therapy, functional decline, and poorer quality of life. Optimal nutritional care consists of a multimodal approach, including screening, dietary counselling, nutritional supplementation, exercise advice, and consideration of prescribable medications. The aim of this article is to review the recent evidence supporting prescribing options in cancer malnutrition and cachexia. RECENT
findingsThe use of olanzapine is supported by high-quality studies and meta-analyses and appears to lead to appetite stimulation, weight gain, and reduced grade 3 chemotherapy-related toxicities. The effect may be greater in those with nausea as a contributing factor to anorexia; and whilst the safety profile of olanzapine appears acceptable, some concerns about tolerability, leukopenia, and functional decline are noted.The evidence for steroids and progestogens is outdated, and more recent studies have highlighted that these medications may worsen cachexia.Low-level evidence exists for mirtazapine and N-3 fatty acids containing DHA. SUMMARY: The role of pharmacotherapy in the management of cancer cachexia is limited, but when indicated, olanzapine has the strongest evidence to support its use and should displace steroids and progestogens as the first-line medication used in supportive oncology and palliative care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.